NCT00352911View on ClinicalTrials.gov

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

November 30, 2007

Conditions
HIV Infections
Interventions
DRUG

VGX-410 (Mifepristone)

DRUG

Placebo for VGX-410 (Mifepristone)

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

Veterans Hospital of Philadelphia, Philadelphia

20007

Georgetown University, Washington D.C.

All Listed Sponsors
lead

VGX Pharmaceuticals, LLC

INDUSTRY

NCT00352911 - Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects | Biotech Hunter | Biotech Hunter